AI is transforming drug design. But designing a molecule is only half the challenge. The other half is understanding what it actually does in biology.

Biology is a dynamic network of thousands of parallel molecular activities. To design better drugs, AI must understand the state of that network and how it responds to intervention.

Molecular assays, morphology profiling and computational models provide different views of biology. But a drug affects an interconnected network, where changes in one activity can influence many others. Understanding these effects requires seeing how they happen together. BioGPU connects selected molecular-activity measurements in a cellular network with evidence that AI agents reason on.

Anima Biotech developed BioGPU to make that possible.

BioGPU is the Cellular Biology Runtime for AI Agents. On BioGPU, AI agents design and run experiments, see inside cellular networks, and discover how they respond to drugs.

BioGPU's Visual Biology technology generates the experimental images. Its Foundation Model, trained on more than 2 billion images of cellular activities, recognizes what is happening and brings that evidence directly into AI.

Anima brings experience across 25 drug-discovery programs, including collaborations with AbbVie, Takeda, and Lilly.

With BioGPU, AI can do more than design molecules. It can see what they do across cellular networks, learn from the results, and design better drugs.